Showing results (261-270 of 283) with videos related to
Sort By:
Pageof 29
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2018
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trialV Urbonas, D Schadendorf, L Zimmer, et al.British Journal of Cancer|April 16, 2009
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanomaR F Kefford, N P B Thomas, P G Corrie, et al.British Journal of Cancer|August 17, 2000
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung CancerH Anderson, P Hopwood, R J Stephens, et al.Journal of Medicinal Chemistry|December 19, 1998
Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chainR S McElhinney, D J Donnelly, J E McCormick, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecanR S Midgley, D J Kerr, K T Flaherty, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2014
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanomaA Gupta, S Love, A Schuh, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancerC Manegold, N van Zandwijk, A Szczesna, et al.Lung Cancer (Amsterdam, Netherlands)|September 3, 2013
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancerT Ciuleanu, C-M Tsai, C-J Tsao, et al.British Journal of Cancer|February 18, 2011
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumoursO A Khan, M Gore, P Lorigan, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanomaM R Middleton, P Friedlander, O Hamid, et al.Pageof 29